Animal Vaccine Market

Animal Vaccine Market Size:

The global animal vaccine market size reached US$ 13.4 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 25.1 Billion by 2032, exhibiting a growth rate (CAGR) of 7.24% during 2024-2032. The increasing pet ownership, rising livestock production, growing awareness of zoonotic diseases, significant advances in vaccine technology, rising favorable government regulations, growing demand for animal-derived food products, and the increasing need for effective disease management and prevention in animals are some of the major factors propelling the growth of the market.

Animal Vaccine Market Analysis:

• Major Market Drivers: The rise in global pet ownership and intensive livestock farming represents the major driver of the market growth. As pets become increasingly integral to families, there is a growing demand for vaccines to ensure their health and longevity. Government regulations mandating vaccination and efforts to control zoonotic diseases also drive market growth, emphasizing the importance of disease prevention.
• Key Market Trends: The advancement of biotechnology and the development of more targeted vaccines represent the key trends in the market. Innovations such as DNA and RNA vaccines are gaining traction, offering improved efficacy and faster production. The increasing focus on personalized veterinary care and the use of digital tools for tracking vaccine administration are also shaping the future of the market.
• Geographical Trends: According to the animal vaccine market overview, North America accounts for the largest region in the market. The high pet ownership rates, extensive livestock farming, and strict regulations are driving the market growth across the region. Significant investment in veterinary research and development (R&D) fuels the market growth in the region. The increasing concerns over zoonotic diseases, advances in vaccine technology, and the rising demand for high-quality, safe animal products also contribute to the market growth.
• Competitive Landscape: Some of the major market players in the animal vaccine industry include C.H. Boehringer Sohn AG & Co. KG, Ceva Sante Animale, Elanco Animal Health Incorporated (Eli Lilly and Company), Hester Biosciences Limited, Hipra S.A., Hygieia Biological Laboratories, Merck & Co. Inc., Phibro Animal Health Corporation, Vaxxinova GmbH (EW Group), Virbac, and Zoetis Services LLC, among many others.
• Challenges and Opportunities: Business opportunities in the animal vaccine market include technological advancements such as mRNA and DNA vaccines, which promise improved efficacy and faster production times. In addition to this, the expanding markets in the developing regions, along with an increased focus on preventive healthcare, and rising investment in research and development (R&D) also present significant growth prospects, driving innovation and improved access to effective animal vaccines. However, the market also faces several challenges such as high development costs, strict regulatory requirements, and issues with vaccine distribution and storage, particularly in remote areas. In line with this, market fragmentation and the need for species-specific vaccines can complicate production.
   

Animal Vaccine Market Trends:

Growing Regulatory and Disease Management Pressures

Stringent regulatory requirements for animal health and disease control contribute to the growing demand for vaccines. Governments and international health organizations emphasize vaccination to manage and prevent zoonotic diseases, which can transfer from animals to humans. For instance, in May 2024, The Department of Animal Husbandry & Dairying (DAHD), Ministry of Fisheries, Animal Husbandry & Dairying, Government of India (GoI) signed a Memorandum of Understanding (MoU) with the United Nations Development Programme (UNDP) India on Digitalization of Vaccine Cold Chain Management, Capacity Building, and Communication Planning. This collaboration marks a significant step toward enhancing animal health and husbandry practices in India, leveraging UNDP's global expertise and DAHD's mandate. This regulatory pressure ensures ongoing investment in vaccine development and deployment, which is creating a positive animal vaccine market outlook.

Expansion of Livestock Production

The rise in global livestock production, driven by increased meat and dairy consumption, is a major factor in the animal vaccine market. In order to manage and prevent outbreaks of diseases that can impact animal health and agricultural productivity, vaccines are crucial. Efficient vaccination programs help mitigate losses and enhance food security, making vaccines an essential component of modern livestock management. For instance, in July 2024, in India, the state government is set to launch the Accredited Agent for Health and Extension of Livestock Production (A-HELP) programme for the first time in the state to boost livestock development and enhance rural livelihood in Uttar Pradesh. This initiative will be spearheaded by the UP State Rural Livelihood Mission (UPSRLM) in collaboration with the animal husbandry department. Such initiatives prove pivotal for facilitating livestock production and development, thereby contributing to the market growth.

Increasing Pet Ownership

The surge in pet ownership, particularly in developed regions like North America and Europe, fuels the demand for animal vaccines. As pets become integral to family life, owners are more inclined to invest in their health and well-being. According to industry reports, as of 2024, 66% of U.S. households (86.9 million homes) own a pet, which is an increase from 56% in 1988, as pet ownership statistics show. From companionship to emotional support, pets are a vital part of their owners’ lives. 97% of pet owners consider their pets to be a part of their family. According to the animal vaccine market forecast, this trend will continue to be further supported by a growing awareness of preventive healthcare for animals, which is expected to lead to a higher uptake of vaccines to protect against diseases and prolong pets’ lives.

Animal Vaccine Market Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the market, along with forecasts at the global, regional, and country levels for 2024-2032. Our report has categorized the market based on product, animal type, and route of administration.

Breakup by Product:

• Attenuated vaccines
• Inactivated vaccines
• Subunit vaccines
• Toxoid vaccines
• Conjugate vaccines
• Recombinant vaccines
• DNA vaccines
   

Attenuated vaccines accounts for the majority of the market share

The report has provided a detailed breakup and analysis of the market based on the product. This includes attenuated vaccines, inactivated vaccines, subunit vaccines, toxoid vaccines, conjugate vaccines, recombinant vaccines, and DNA vaccines. According to the animal vaccine market report, attenuated vaccines represented the largest segment.

Attenuated vaccines, which are created from weakened forms of pathogens, are playing a significant role in driving the market growth. These vaccines are designed to stimulate a strong immune response in animals while posing minimal risk of causing disease. Attenuated vaccines offer several advantages, including long-lasting protection, single-dose administration, and cost-effectiveness. Their efficacy in preventing infectious diseases in animals has led to increased adoption by veterinarians and livestock producers. The growing demand for livestock products, rising awareness about zoonotic diseases, and the need to ensure animal health and welfare are key factors contributing to the expansion of the market, with attenuated vaccines at the forefront of this growth.

Breakup by Animal Type:

• Companion animal  
  • Dogs
  • Cats
• Livestock animal  
  • Cattle
  • Pigs
  • Sheep
  • Others
     

Livestock animal holds the largest share of the industry

A detailed breakup and analysis of the market based on the animal type has also been provided in the report. This includes companion animal (dogs and cats), livestock animal (cattle, pigs, sheep, and others).  According to the report, livestock animal accounted for the largest animal vaccine market share.

The global demand for livestock products, such as meat, milk, and eggs, is steadily rising due to population growth and changing dietary preferences. In order to meet this demand, farmers and livestock producers are increasingly focusing on improving animal health and preventing diseases. Vaccination plays a pivotal role in achieving these goals by safeguarding animals from infectious diseases, improving their overall well-being, and enhancing productivity. Consequently, the need for effective and efficient animal vaccines is escalating, thus prompting continuous research and development (R&D) in this field.

Breakup by Route of Administration:

• Subcutaneous
• Intramuscular
• Intranasal
• Others
   

Subcutaneous represents the leading market segment 

The report has provided a detailed breakup and analysis of the market based on the route of administration. This includes subcutaneous, intramuscular, intranasal, and others. According to the report, subcutaneous represented the largest segment.

Subcutaneous injection is a relatively simple and safe method that can be easily performed by veterinarians or trained personnel. It is administered just beneath the skin, allowing for efficient absorption of the vaccine into the bloodstream. This route also provides a sustained release of the vaccine, leading to longer-lasting immune responses, thereby facilitating the animal vaccine demand. Additionally, subcutaneous administration allows for the simultaneous administration of multiple vaccines in different locations, reducing the need for multiple injections. These factors contribute to the widespread adoption of subcutaneous administration in the market.

Breakup by Region:

• North America
  • United States
  • Canada
• Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Others
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Others
• Latin America
  • Brazil
  • Mexico
  • Others
• Middle East and Africa
   

North America leads the market, accounting for the largest animal vaccine market share

The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Europe (Germany, France, the United Kingdom, Italy, Spain, and others); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America represents the largest regional market for animal vaccine.

The region has a significant livestock industry, including cattle, and swine, which requires robust vaccination programs to ensure animal health and productivity which is acting as one of the major animal vaccine market growth factors across the region. The demand for livestock products in North America is high, driven by growing population, increasing disposable incomes, and dietary preferences. Consequently, there is a strong emphasis on preventing diseases and maintaining high-quality animal products, leading to a higher adoption of animal vaccines. North America has a well-established veterinary healthcare system and stringent regulatory standards for animal health. This supports the development, registration, and distribution of animal vaccines, encouraging innovation and investment in the market. The presence of leading pharmaceutical companies and vaccine manufacturers in the region further boosts the availability and accessibility of animal vaccines. For instance, in June 2024, MSD Animal Health, a division of Merck & Co., Inc., Rahway, N.J., USA announced the launch and availability of the NOBIVAC® NXT Rabies portfolio – consisting of NOBIVAC® NXT Feline-3 Rabies and NOBIVAC® NXT Canine-3 Rabies – in Canada as part of the company’s ongoing dedication to rabies protection.

Competitive Landscape:

• The market research report has also provided a comprehensive analysis of the competitive landscape in the market. Detailed profiles of all major companies have also been provided. Some of the major market players in the animal vaccine industry include C.H. Boehringer Sohn AG & Co. KG, Ceva Sante Animale, Elanco Animal Health Incorporated (Eli Lilly and Company), Hester Biosciences Limited, Hipra S.A., Hygieia Biological Laboratories, Merck & Co. Inc., Phibro Animal Health Corporation, Vaxxinova GmbH (EW Group), Virbac, and Zoetis Services LLC, etc.
  
  (Please note that this is only a partial list of the key players, and the complete list is provided in the report.)
   
• The market for animal vaccine is highly competitive, featuring major players like Zoetis, Merck Animal Health, and Elanco, who led in innovation and market share. Animal vaccine companies compete through advanced vaccine technologies, extensive product portfolios, and strategic mergers and acquisitions. Regional players and new entrants also contribute by offering specialized vaccines and expanding into emerging markets. The competitive landscape is driven by the need for effective disease management, regulatory compliance, and growing demand for both companion animal and livestock vaccines. For instance, in June 2024, Gavi, the Vaccine Alliance, in collaboration with partners, announced support for human rabies vaccines for post-exposure prophylaxis (PEP) as part of routine immunization. Eligible countries are receiving guidance on how to access these vaccines under Gavi’s cofinancing policy.

Animal Vaccine Market News:

• In October 2023, the Centre for Veterinary Vaccine Innovation and Manufacturing (CVIM) at The Pirbright Institute signed a Memorandum of Understanding (MOU) with The University of Saskatchewan’s (USask) Vaccine and Infectious Disease Organization (VIDO). The MOU allows for expanded collaborations and training around vaccine manufacturing to drive innovations for animal health.
• In July 2024, Merck Animal Health, known as MSD Animal Health outside of the United States and Canada, a division of Merck & Co., Inc., Rahway, N.J., USA announced the completion of its acquisition of the aqua business of Elanco Animal Health Incorporated. The completion of this acquisition bolsters Merck Animal Health’s position in the aqua industry with a comprehensive approach to promoting fish health, welfare, and sustainability in aquaculture, conservation, and fisheries.

Animal Vaccine Market Report Scope:

Key Questions Answered in This Report:

• How has the global animal vaccine market performed so far, and how will it perform in the coming years?
• What are the drivers, restraints, and opportunities in the global animal vaccine market?
• What is the impact of each driver, restraint, and opportunity on the global animal vaccine market?
• What are the key regional markets?
• Which countries represent the most attractive animal vaccine market?
• What is the breakup of the market based on the product?
• Which is the most attractive product in the animal vaccine market?
• What is the breakup of the market based on the animal type?
• Which is the most attractive animal type in the animal vaccine market?
• What is the breakup of the market based on the route of administration?
• Which is the most attractive route of administration in the animal vaccine market?
• What is the competitive structure of the market?
• Who are the key players/companies in the global animal vaccine market?

Key Benefits for Stakeholders:

• IMARC’s industry report offers a comprehensive quantitative analysis of various market segments, historical and current market trends, market forecasts, and dynamics of the animal vaccine market from 2018-2032.
• The research report provides the latest information on the market drivers, challenges, and opportunities in the global animal vaccine market.
• The study maps the leading, as well as the fastest-growing, regional markets. It further enables stakeholders to identify the key country-level markets within each region.
• Porter's five forces analysis assists stakeholders in assessing the impact of new entrants, competitive rivalry, supplier power, buyer power, and the threat of substitution. It helps stakeholders to analyze the level of competition within the animal vaccine industry and its attractiveness.
• The competitive landscape allows stakeholders to understand their competitive environment and provides insight into the current positions of key players in the market.